Impact of dopamine and dobutamine support at the initiation of epoprostenol on short and long-term survival in patients with pulmonary arterial hypertension

被引：0
|
作者：
Akagi, S. [1 ]
Matsubara, H. [2 ]
Miyaji, K. [2 ]
Ogawa, A. [2 ]
Kusano, K. [1 ]
Ito, H. [1 ]
机构：
[1] Okayama Univ, Dept Cardiovasc Med, Okayama 7008530, Japan
[2] Natl Hosp Org, Okayama Med Ctr, Okayama, Japan
来源：
EUROPEAN HEART JOURNAL | 2012年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：422 / 422
页数：1
相关论文
共 50 条
  • [1] Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension
    Simonneau, Gerald
    Rubin, Lewis J.
    Galie, Nazzareno
    Barst, Robyn J.
    Fleming, Thomas R.
    Frost, Adaani
    Engel, Peter
    Kramer, Mordechai R.
    Serdarevic-Pehar, Marjana
    Layton, Gary R.
    Sitbon, Olivier
    Badesch, David B.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2014, 33 (07): : 689 - 697
  • [2] Long-term survival comparison in patients with primary and secondary pulmonary arterial hypertension treated with chronic epoprostenol therapy
    Bedi, MS
    Spates-Panyon, J
    Mathier, MM
    Kapoor, A
    MacGowan, GA
    McNamara, DM
    Murali, S
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (06) : 258A - 258A
  • [3] Long-term Effects of Epoprostenol on the Pulmonary Vasculature in Idiopathic Pulmonary Arterial Hypertension
    Rich, Stuart
    Pogoriler, Jennifer
    Husain, Aliya N.
    Toth, Peter T.
    Gomberg-Maitland, Mardi
    Archer, Stephen L.
    CHEST, 2010, 138 (05) : 1234 - 1239
  • [4] Cutaneous findings in patients with pulmonary arterial hypertension receiving long-term epoprostenol therapy
    Myers, SA
    Ahearn, GS
    Selim, MA
    Tapson, VE
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 51 (01) : 98 - 102
  • [5] Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH)
    Calcaianu, George
    Calcaianu, Mihaela
    Canuet, Matthieu
    Enache, Irina
    Kessler, Romain
    PULMONARY CIRCULATION, 2017, 7 (02) : 439 - 447
  • [6] Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH)
    Calcaianu, George
    Chaouat, Ari
    Canuet, Matthieu
    Kessler, Romain
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [7] Long-term safety of a new formulation of epoprostenol in pulmonary arterial hypertension
    Delcroix, Marion
    Simonneau, Gerald
    Bergot, Emmanuel
    Boonstra, Anco
    Granton, John
    Langleben, David
    Subias, Pilar Escribano
    Galie, Nazzareno
    Pfister, Thomas
    Lemarie, Jean-Christophe
    Sitbon, Olivier
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [8] Successful withdrawal of long-term epoprostenol therapy for pulmonary arterial hypertension
    Kim, NH
    Channick, RN
    Rubin, LJ
    CHEST, 2003, 124 (04) : 1612 - 1615
  • [9] Short-term improvement in pulmonary hemodynamics is strongly predictive of long-term survival in patients with pulmonary arterial hypertension
    Tiede, Henning
    Sommer, Natascha
    Milger, Katrin
    Voswinckel, Robert
    Bandorski, Dirk
    Schermuly, Ralph T.
    Weissmann, Norbert
    Grimminger, Friedrich
    Seeger, Werner
    Ghofrani, Hossein A.
    PULMONARY CIRCULATION, 2013, 3 (03) : 523 - +
  • [10] Long-term survival of systemic sclerosis with pulmonary arterial hypertension patients
    Sirijanchune, Piyaporn
    Lhakum, Panomkorn
    RESPIROLOGY, 2023, 28 : 26 - 27
12345